Drug Profile
Triptorelin extended release - Xbrane
Alternative Names: Microrelin; SpherotideLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Primm srl
- Developer Pooyesh Darou; Xbrane
- Class Antineoplastics; Antivirals; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Endometriosis; Prostate cancer; Uterine leiomyoma
- No development reported Breast cancer; Precocious puberty
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Prostate-cancer in Denmark (IV-injection, Controlled release)
- 28 Aug 2020 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer in Sweden
- 28 Aug 2020 No recent reports of development identified for clinical-Phase-Unknown development in Precocious-puberty in Sweden